CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:10 p.m. EST in New York.
A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at www.iderapharma.com or at the link http://www.veracast.com/webcasts/stifel/healthcare2014/05213390623.cfm. An archived version will also be available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.
CONTACT: Investor and Media Contact:
Jim Baker
Executive Director, Corporate Affairs
Idera Pharmaceuticals
617-679-5516
jbaker@iderapharma.com
Idera Pharmaceuticals
